

**Comparison of long-term efficacy and safety of esketamine nasal spray plus oral antidepressant in younger versus older patients with treatment-resistant depression: post-hoc analysis of SUSTAIN-2, a long-term open-label phase 3 safety and efficacy study**

Ochs-Ross R, Wajs E, Daly EJ, Zhang Y, Lane R, Lim P, Drevets WC, Steffens DC, Sanacora G, Jamieson C, Hough D, Manji H, Singh JB.

American journal of geriatric psychiatry  
2021; ePub(ePub):ePub

**ARTICLE IDENTIFIERS**

DOI: 10.1016/j.jagp.2021.09.014

PMID: 34750057

PMCID: not available

**JOURNAL IDENTIFIERS**

LCCN: not available

pISSN: 1064-7481

eISSN: 1545-7214

OCLC ID: 26387933

CONS ID: not available

US National Library of Medicine ID: 9309609

This article was identified from a query of the SafetyLit database.